CGCG clinical practice guidelines for the management of adult diffuse gliomas.
暂无分享,去创建一个
Yu Wang | Lei Han | Pei Yang | Wei Yan | Shaowu Li | Ying Mao | Yuan Yang | Jing Chen | Qing Mao | Hongmin Bai | Tao Jiang | Yu Yao | Jun Dong | Zhixiong Lin | Chuanbao Zhang | Zheng Wang | Xiaoguang Qiu | Chunsheng Kang | Xing Liu | Ke Sai | Xinting Wei | Zhaoshi Bao | Zheng Wang | Y. Mao | T. Jiang | Chuanlu Jiang | Xuejun Li | C. Kang | Y. You | Yan-wei Liu | Huimin Hu | Hongmin Bai | Weimin Wang | Q. Mao | K. Sai | J. Chen | Xing Fan | Yu Yao | Yu Wang | Wenbin Ma | Xing Liu | Shaowu Li | Shuai Liu | Yongzhi Wang | Chuanbao Zhang | Baoshi Chen | Wenbin Li | Z. Bao | Wei Yan | Wei Zhang | K. Yao | X. Qiu | Xuejun Yang | Xiaodong Ma | Xing Fan | Yuan Yang | Yanwei Liu | Huimin Hu | Yinyan Wang | Kun Yao | Wei Zhang | Qixue Wang | Anhua Wu | Gan You | Yongzhi Wang | Chuanlu Jiang | Yongping You | Zhixiong Liu | Yu-Qing Liu | S. Lv | Jun Dong | Ling Chen | Wenbin Ma | Jinquan Cai | Zhixiong Liu | A. Wu | Shuai Liu | Xuejun Yang | Xuejun Li | Ling Chen | Weimin Wang | Wenbin Li | Shouwei Li | Guilin Li | Baoshi Chen | Xianzhi Liu | Zhiwen Zhang | Yiwu Dai | Shengqing Lv | Liang Wang | Guozheng Xu | Xiaodong Ma | Hongjun Wang | Lingchao Chen | Yuqing Liu | Zhiliang Wang | Guozheng Xu | Guilin Li | Jinquan Cai | Lei Han | G. You | Shouwei Li | Qi-xue Wang | Pei Yang | Xinting Wei | Zhiwen Zhang | Hongjun Wang | Zhixiong Lin | Zheng Wang | Liang Wang | Yiwu Dai | Yin-yan Wang | Lingchao Chen | Zhiliang Wang | Xianzhi Liu | Chuan-bao Zhang | Qixue Wang | Xiaoguang Qiu | Yanwei Liu
[1] T. Jiang,et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma , 2016, Oncoimmunology.
[2] T. Jiang,et al. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. , 2012, Neuro-oncology.
[3] T. Jiang,et al. Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors , 2015, Oncotarget.
[4] T. Jiang,et al. Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma. , 2011, Chinese medical journal.
[5] John A Butman,et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Susan M. Chang,et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[8] E. Shaw,et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. , 2008, Journal of neurosurgery.
[9] D. Brachman,et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study , 2017, The Lancet.
[10] T. Tominaga,et al. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion , 2016, Journal of Neuro-Oncology.
[11] G. Reifenberger,et al. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] E. Shaw,et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.
[13] Susan M. Chang,et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). , 2010, Neuro-oncology.
[14] K. Hoang-Xuan,et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[15] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[16] S. Li,et al. Anatomic Location of Tumor Predicts the Accuracy of Motor Function Localization in Diffuse Lower-Grade Gliomas Involving the Hand Knob Area , 2017, American Journal of Neuroradiology.
[17] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[18] Caterina Giannini,et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] C. Sommer,et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] G. Reifenberger,et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Pieter Wesseling,et al. International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.
[23] M. J. van den Bent,et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis , 2017, Neuro-oncology.
[24] M. Nikiforova,et al. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. , 2014, Neuro-oncology.
[25] Zhifeng Shi,et al. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas , 2015, Modern Pathology.
[26] Ying Zheng,et al. Transition over 35 years in the incidence rates of primary central nervous system tumors in Shanghai, China and histological subtyping based on a single center experience spanning 60 years. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[27] T. Jiang,et al. Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution , 2013, Journal of Neuro-Oncology.
[28] Dario J. Englot,et al. Extent of Surgical Resection Predicts Seizure Freedom in Low-Grade Temporal Lobe Brain Tumors , 2012, Neurosurgery.
[29] Dieta Brandsma,et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.
[30] J. Perry. Thromboembolic disease in patients with high-grade glioma. , 2012, Neuro-oncology.
[31] Y. Marie,et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes , 2014, Neurology.
[32] R Grant,et al. Guidelines on management of low‐grade gliomas: report of an EFNS–EANO * Task Force , 2010, European journal of neurology.
[33] J. Doudna,et al. Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma , 2011 .
[34] Timothy C. Ryken,et al. Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery , 2008, Journal of Neuro-Oncology.
[35] David T. W. Jones,et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.
[36] M. Chamberlain. Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study , 2015, Journal of Neuro-Oncology.
[37] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[38] Michael Platten,et al. Treatment of anaplastic glioma. , 2015, Cancer treatment and research.
[39] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[40] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[41] F. Jolesz,et al. Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance , 2005, Cancer.
[42] B. Fisher,et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Winand N M Dinjens,et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] S. Coons,et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. , 2015, International journal of radiation oncology, biology, physics.
[45] Martin Sill,et al. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. , 2014, Neuro-oncology.
[46] J. Tonn,et al. Molecular imaging of gliomas with PET: opportunities and limitations. , 2011, Neuro-oncology.
[47] R. McLendon,et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. , 2011, Neuro-oncology.
[48] Lei Wang,et al. Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China , 2012, PloS one.
[49] C. Finch,et al. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures , 2010, Journal of Neuro-Oncology.
[50] R. McLendon,et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas , 2012, Oncotarget.
[51] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[52] Satoshi O. Suzuki,et al. Differentiating primary CNS lymphoma from glioblastoma multiforme: assessment using arterial spin labeling, diffusion-weighted imaging, and 18F-fluorodeoxyglucose positron emission tomography , 2013, Neuroradiology.
[53] A. Viale,et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.
[54] Cynthia Ménard,et al. Advances in Magnetic Resonance Imaging and Positron Emission Tomography Imaging for Grading and Molecular Characterization of Glioma. , 2015, Seminars in radiation oncology.
[55] In-Hee Lee,et al. Spatiotemporal Evolution of the Primary Glioblastoma Genome. , 2015, Cancer cell.
[56] E. Shaw,et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. , 2014 .
[57] H. Iseki,et al. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI. , 2017, Journal of neurosurgery.
[58] Yun Yen,et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[59] Michael A. Choti,et al. DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.
[60] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[61] A. Jemal,et al. Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.
[62] Roland Eils,et al. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma , 2016, Nature Medicine.
[63] M. Mehta,et al. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 , 2018, Neuro-oncology.
[64] P. Varlet,et al. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours , 2017, Acta Neuropathologica Communications.
[65] M. Nykter,et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. , 2013, The Journal of clinical investigation.
[66] M. Chan. Recent Technical Advances and Indications for Radiation Therapy in Low-Grade Glioma. , 2015, Seminars in radiation oncology.
[67] E. Shaw,et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] Steven J. M. Jones,et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.
[69] David T. W. Jones,et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma , 2014, Acta Neuropathologica.
[70] P. Kleihues,et al. TERT promoter mutations in primary and secondary glioblastomas , 2013, Acta Neuropathologica.
[71] Ashley R. Woodfin,et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas , 2017, Nature Medicine.
[72] Satoru Miyano,et al. Mutational landscape and clonal architecture in grade II and III gliomas , 2015, Nature Genetics.
[73] E. Chiocca,et al. Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. , 2015, Neuro-oncology.
[74] B. Rosen,et al. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma , 2017, Journal of Neuro-Oncology.
[75] Susan M. Chang,et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? , 2011, Neuro-oncology.
[76] B. Nahed,et al. Low-grade gliomas. , 2014, The oncologist.
[77] Naoya Hashimoto,et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.
[78] Denis Lacombe,et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] M. J. van den Bent,et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] J. Mcsherry. Spice, pot, and stroke , 2014, Neurology.
[81] E. Shaw,et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] M. Taphoorn,et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures , 2009, Journal of Neurology.
[83] Chao You,et al. Statistical Report of Central Nervous System Tumors Histologically Diagnosed in the Sichuan Province of China from 2008 to 2013: A West China Glioma Center Report , 2016, Annals of Surgical Oncology.
[84] Jennie W. Taylor,et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT , 2017, Acta Neuropathologica.
[85] H. Duffau. Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up , 2015, Acta Neurochirurgica.
[86] T. Jiang,et al. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry , 2015, Oncotarget.
[87] Luciano Fadiga,et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article. , 2012, Journal of neurosurgery.
[88] A. Vortmeyer,et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression , 2015, Nature Genetics.
[89] D. Orringer,et al. Advances in the Surgical Management of Low-Grade Glioma. , 2015, Seminars in radiation oncology.
[90] N. Laperriere,et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[91] S. Taillibert,et al. Anaplastic glioma: current treatment and management , 2015, Expert review of neurotherapeutics.
[92] G. Reifenberger,et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. , 2013, Cancer cell.
[93] A. Verma. MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .
[94] P. Lanteri,et al. Surgical treatment of high-grade gliomas in motor areas. The impact of different supportive technologies: a 171-patient series , 2010, Journal of Neuro-Oncology.
[95] Mitchel S Berger,et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. , 2008, Journal of neurosurgery.
[96] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[97] L. C. Hinske,et al. In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing , 2013, Acta Neuropathologica.
[98] Gary L. Gallia,et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.
[99] L. Recht,et al. Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors , 2000, Neurology.
[100] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[101] R. Stupp,et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. , 2012, European journal of cancer.
[102] L. Deangelis,et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] G. Reifenberger,et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.
[104] Act Investigators. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial , 2017 .
[105] T. Holland-Letz,et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis , 2013, Acta Neuropathologica.
[106] Xiuli Wang,et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.
[107] Henry Brem,et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. , 2009, Journal of neurosurgery.
[108] C. Vecht,et al. Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids. , 2016, Neuro-oncology practice.
[109] B. Porse,et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas , 2017, Nature Medicine.
[110] L Junck,et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. , 2011, The Lancet. Oncology.
[111] M. Berger,et al. Differentiation of Glioblastoma Multiforme and Single Brain Metastasis by Peak Height and Percentage of Signal Intensity Recovery Derived from Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging , 2007, American Journal of Neuroradiology.
[112] E. Bruera,et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[114] Y. Marie,et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes , 2014, Neurology.
[115] Mitchel S Berger,et al. An extent of resection threshold for newly diagnosed glioblastomas. , 2011, Journal of neurosurgery.
[116] A. Iavarone,et al. Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma , 2015, Clinical Cancer Research.
[117] Guido Reifenberger,et al. Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma‐Tailored Gene Panel , 2017, Brain pathology.
[118] K. Hoang-Xuan,et al. MGMT methylation: A marker of response to temozolomide in low‐grade gliomas , 2006, Annals of neurology.
[119] J. Buckner,et al. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma , 2017, Journal of Neuro-Oncology.
[120] T. Jiang,et al. Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China , 2013, Journal of Cancer Research and Clinical Oncology.
[121] G. Reifenberger,et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation , 2013, Neurology.
[122] N. Pouratian,et al. Surgery Insight: the role of surgery in the management of low-grade gliomas , 2007, Nature Clinical Practice Neurology.
[123] Paul S Mischel,et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[124] S. Frisch,et al. Post-Surgical Language Reorganization Occurs in Tumors of the Dominant and Non-Dominant Hemisphere , 2017, Clinical Neuroradiology.
[125] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[126] R. Stupp,et al. Epilepsy in brain tumor patients. , 2010, Current opinion in neurology.
[127] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[128] John B. Shoven,et al. I , Edinburgh Medical and Surgical Journal.
[129] D. Osoba,et al. Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma , 2017, The New England journal of medicine.
[130] J. Akers,et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas , 2014, Genome research.
[131] R. Stupp,et al. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082) , 2016, Clinical Cancer Research.
[132] M Brada,et al. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[133] W. Dinjens,et al. Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification , 2017, Acta Neuropathologica.
[134] Y. Marie,et al. O6.08COMBINED ANALYSIS OF TERT, EGFR AND IDH STATUS DEFINE DISTINCT PROGNOSTIC CLASSES OF GLIOBLASTOMA , 2014 .
[135] T. Jiang,et al. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas , 2015, PloS one.
[136] Didier Frappaz,et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[137] G. Reifenberger,et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. , 2014, The Lancet. Oncology.
[138] H Duffau,et al. Temozolomide for low-grade gliomas , 2007, Neurology.
[139] G. Reifenberger,et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[140] D. Brat,et al. Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.
[141] David J. Yang,et al. Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.
[142] M. Weller,et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide , 2010, Journal of Neuro-Oncology.
[143] Alexander R. Pico,et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.
[144] G. Reifenberger,et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. , 2015, Neuro-oncology.
[145] Chul-Kee Park,et al. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas , 2017, Acta Neuropathologica Communications.
[146] Zhifeng Shi,et al. Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors , 2014, Modern Pathology.
[147] R. McLendon,et al. Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.
[148] R. Stupp,et al. Epilepsy meets cancer: when, why, and what to do about it? , 2012, The Lancet. Oncology.
[149] Frank M. Sacks,et al. IDH 1 and IDH 2 Mutations in Gliomas , 2009 .
[150] V. Tabar,et al. The Role of Extent of Resection in IDH1 Wild‐Type or Mutant Low‐Grade Gliomas , 2018, Neurosurgery.
[151] T. Jiang,et al. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. , 2016, Neuro-oncology.
[152] G. Reifenberger,et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[153] G. Spena,et al. Supratentorial Gliomas in Eloquent Areas: Which Parameters Can Predict Functional Outcome and Extent of Resection? , 2013, PloS one.
[154] M. Rosenblum,et al. Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”? , 2014, Acta Neuropathologica.
[155] Raul Rabadan,et al. The integrated landscape of driver genomic alterations in glioblastoma , 2013, Nature Genetics.
[156] Luc Taillandier,et al. Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.
[157] In-Hee Lee,et al. Clonal evolution of glioblastoma under therapy , 2016, Nature Genetics.
[158] H. Donovan,et al. I could lose everything: understanding the cost of a brain tumor , 2007, Journal of Neuro-Oncology.
[159] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[160] K. Hoang-Xuan,et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations , 2014, British Journal of Cancer.
[161] G. Reifenberger,et al. MGMT testing—the challenges for biomarker-based glioma treatment , 2014, Nature Reviews Neurology.
[162] Martin Sill,et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma , 2014, Acta Neuropathologica.
[163] K. Hopkins,et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[164] D. Brachman,et al. A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424. , 2013 .
[165] Cancer Care Ontario Practice Guidelines Initiative , 2003 .
[166] Geirmund Unsgård,et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. , 2012, JAMA.
[167] Tao Jiang,et al. Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. , 2011, Chinese medical journal.
[168] E. Galanis,et al. Medical management of high-grade astrocytoma: current and emerging therapies. , 2014, Seminars in oncology.
[169] K. Hoang-Xuan,et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 , 2010, Neurology.
[170] B. Scheithauer,et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[171] K. Hoadley,et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. , 2012, Neuro-oncology.
[172] Hugues Duffau,et al. Surgery of low-grade gliomas: towards a ‘functional neurooncology’ , 2009, Current opinion in oncology.
[173] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[174] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[175] J. Uhm. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group , 2010 .
[176] Gabriele Schackert,et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups , 2015, Acta Neuropathologica.
[177] Albert Lai,et al. Time course of imaging changes of GBM during extended bevacizumab treatment , 2008, Journal of Neuro-Oncology.
[178] G. Reifenberger,et al. Molecular neuro-oncology in clinical practice: a new horizon. , 2013, The Lancet. Oncology.
[179] Ludomir Stefańczyk,et al. Cortical mapping by functional magnetic resonance imaging in patients with brain tumors , 2005, European Radiology.
[180] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[181] T. Jiang,et al. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples , 2014, Oncotarget.
[182] P. Cochat,et al. Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.
[183] A. Karim,et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[184] M. Weller,et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. , 2017, The Lancet. Oncology.
[185] K. Hoang-Xuan,et al. Chromosome 1p loss: A favorable prognostic factor in low‐grade gliomas , 2005, Annals of neurology.
[186] Luca Regli,et al. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.
[187] F. Lieberman,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.
[188] David T. W. Jones,et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma , 2014, Acta Neuropathologica.
[189] Ying Mao,et al. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas , 2015, Oncotarget.
[190] Raymond Sawaya,et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[191] Susan M. Chang,et al. Response Assessment in Neuro-Oncology Clinical Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[192] H. Duffau,et al. Supratotal resection of diffuse gliomas - an overview of its multifaceted implications. , 2017, Neuro-Chirurgie.
[193] H. Iseki,et al. Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype. , 2013, Neurologia medico-chirurgica.
[194] Miss A.O. Penney. (b) , 1974, The New Yale Book of Quotations.